DMK Pharmaceuticals Corporation

OTCPK:DMKP.Q Voorraadrapport

Marktkapitalisatie: US$10.0

DMK Pharmaceuticals Beheer

Beheer criteriumcontroles 0/4

We currently do not have sufficient information about the CEO.

Belangrijke informatie

Eddie Glover

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOno data
Eigendom CEOn/a
Management gemiddelde ambtstermijngeen gegevens
Gemiddelde ambtstermijn bestuurgeen gegevens

Recente managementupdates

Recent updates

Adamis Pharmaceuticals: Managing A Position In A Company Diagnosed With Chronic Failure

Sep 30

Next meeting of data safety board to review Adamis Pharma's COVID treatment in Sept.

Jul 29

Adamis CEO urges stock split approval, slate of directors in letter to shareholders

Jul 21

Adamis Pharmaceuticals: Preparing For Another Round Of Success, Failure, Then Hope

Apr 13

Adamis Pharmaceuticals: Market Continues To Overlook TEMPOL's Potential To Be A Leading COVID-19 Therapeutic

Jan 20

Adamis Pharmaceuticals: It's Now Or Never

Dec 02

Adamis Pharmaceuticals: TEMPOL's Near-Term And Long-Term Upside Improves As Variants Sidestep Vaccines

Sep 03

Adamis Pharmaceuticals: Potential COVID Drug Could Reignite Shares

Jun 13

Adamis Pharma gains 9% after Tempol shows potential as an antiviral drug for COVID-19

Jun 07

Adamis pharmaceuticals gets deficiency letter from NASDAQ

May 28

Adamis Pharmaceuticals (ADMP) trades sharply lower after pricing public offering

Jan 29

Adamis Pharma plunges 43% on FDA rejection of Zimhi application for opioid overdose

Nov 16

Adamis Pharmaceuticals EPS misses by $0.01, misses on revenue

Nov 09

CEO

Eddie Glover (74 yo)

no data

Tenure

Mr. Eddie Wabern Glover serves as Chief Executive Officer of US Compounding Inc at DMK Pharmaceuticals Corporation (formerly known as Adamis Pharmaceuticals Corporation). He co-founded US Compounding, Inc....